Literature DB >> 8477877

Islet amyloid polypeptide: demonstration of mRNA in human pancreatic islets by in situ hybridization in islets with and without amyloid deposits.

G T Westermark1, L Christmanson, G Terenghi, J Permerth, C Betsholtz, J Larsson, J M Polak, P Westermark.   

Abstract

Islet amyloid polypeptide which is normally coexpressed with insulin in beta cells, forms amyloid deposits especially in islets of Type 2 (non-insulin-dependent) diabetic subjects. Occurrence of islet amyloid is paradoxically associated with loss of islet amyloid polypeptide immunoreactivity in beta cells. The present study was undertaken to examine whether the islet amyloid polypeptide gene is expressed in islets with decreased islet amyloid polypeptide immunoreactivity. Pancreatic tissue from 14 patients, 7 with Type 2 diabetes and 7 non-diabetic, were obtained at autopsy or surgery and studied for islet amyloid polypeptide expression by in situ hybridization and for presence of insulin and islet amyloid polypeptide by immunohistochemistry. Six of the specimens from the diabetic and three of those from the non-diabetic patients had varying degrees of islet amyloid polypeptide-derived islet amyloid. Amyloid deposits were associated with decreased numbers of beta cells with islet amyloid polypeptide immunoreactivity despite an apparent normal frequency of insulin-containing cells. This discrepancy might reflect an alteration in islet amyloid polypeptide production or processing at a transcriptional or post-transcriptional level. In contrast to the varying immunohistochemical patterns, islets of all categories showed strong labelling using an islet amyloid polypeptide probe for in situ hybridization. It is concluded that islet amyloid polypeptide production is not altered at the transcriptional level. The following possibilities remain: (1) islet amyloid polypeptide production may be altered at a post-transcriptional level or (2) that islet amyloid polypeptide production is normal but the reduced immunoreactivity of the cells reflects a reduced storage of IAPP in secretory granules.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8477877     DOI: 10.1007/bf00400235

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  31 in total

1.  Islet amyloid polypeptide amide causes peripheral insulin resistance in vivo in dogs.

Authors:  R Sowa; T Sanke; J Hirayama; H Tabata; H Furuta; S Nishimura; K Nanjo
Journal:  Diabetologia       Date:  1990-02       Impact factor: 10.122

2.  Islet amyloid polypeptide: pinpointing amino acid residues linked to amyloid fibril formation.

Authors:  P Westermark; U Engström; K H Johnson; G T Westermark; C Betsholtz
Journal:  Proc Natl Acad Sci U S A       Date:  1990-07       Impact factor: 11.205

3.  Basal and stimulated plasma levels of pancreatic amylin indicate its co-secretion with insulin in humans.

Authors:  E Hartter; T Svoboda; B Ludvik; M Schuller; B Lell; E Kuenburg; M Brunnbauer; W Woloszczuk; R Prager
Journal:  Diabetologia       Date:  1991-01       Impact factor: 10.122

4.  Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures.

Authors:  S M Hsu; L Raine; H Fanger
Journal:  J Histochem Cytochem       Date:  1981-04       Impact factor: 2.479

5.  Impaired glucose tolerance is associated with increased islet amyloid polypeptide (IAPP) immunoreactivity in pancreatic beta cells.

Authors:  K H Johnson; T D O'Brien; K Jordan; P Westermark
Journal:  Am J Pathol       Date:  1989-08       Impact factor: 4.307

6.  Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients.

Authors:  G J Cooper; A C Willis; A Clark; R C Turner; R B Sim; K B Reid
Journal:  Proc Natl Acad Sci U S A       Date:  1987-12       Impact factor: 11.205

7.  Islet amyloid polypeptide-like immunoreactivity in the islet B cells of type 2 (non-insulin-dependent) diabetic and non-diabetic individuals.

Authors:  P Westermark; E Wilander; G T Westermark; K H Johnson
Journal:  Diabetologia       Date:  1987-11       Impact factor: 10.122

8.  Effects of meal ingestion on plasma amylin concentration in NIDDM and nondiabetic humans.

Authors:  P C Butler; J Chou; W B Carter; Y N Wang; B H Bu; D Chang; J K Chang; R A Rizza
Journal:  Diabetes       Date:  1990-06       Impact factor: 9.461

9.  Localisation of islet amyloid peptide in lipofuscin bodies and secretory granules of human B-cells and in islets of type-2 diabetic subjects.

Authors:  A Clark; C A Edwards; L R Ostle; R Sutton; J B Rothbard; J F Morris; R C Turner
Journal:  Cell Tissue Res       Date:  1989-07       Impact factor: 5.249

10.  A novel peptide in the calcitonin gene related peptide family as an amyloid fibril protein in the endocrine pancreas.

Authors:  P Westermark; C Wernstedt; E Wilander; K Sletten
Journal:  Biochem Biophys Res Commun       Date:  1986-11-14       Impact factor: 3.575

View more
  5 in total

Review 1.  The age related amyloids: a growing family of unique biochemical substances.

Authors:  G G Cornwell; K H Johnson; P Westermark
Journal:  J Clin Pathol       Date:  1995-11       Impact factor: 3.411

2.  Medin: an integral fragment of aortic smooth muscle cell-produced lactadherin forms the most common human amyloid.

Authors:  B Häggqvist; J Näslund; K Sletten; G T Westermark; G Mucchiano; L O Tjernberg; C Nordstedt; U Engström; P Westermark
Journal:  Proc Natl Acad Sci U S A       Date:  1999-07-20       Impact factor: 11.205

3.  Rapid deposition of amyloid in human islets transplanted into nude mice.

Authors:  P Westermark; D L Eizirik; D G Pipeleers; C Hellerström; A Andersson
Journal:  Diabetologia       Date:  1995-05       Impact factor: 10.122

Review 4.  Amyloid in the islets of Langerhans: thoughts and some historical aspects.

Authors:  Per Westermark
Journal:  Ups J Med Sci       Date:  2011-05       Impact factor: 2.384

5.  Transthyretin and amyloid in the islets of Langerhans in type-2 diabetes.

Authors:  Gunilla T Westermark; Per Westermark
Journal:  Exp Diabetes Res       Date:  2008
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.